Singapore Pharma Firms Eye US Investment Amid Tariff Uncertainty

Pharmaceutical companies in Singapore are actively seeking clarity on tariff exemptions as they plan significant investments in the United States. Deputy Prime Minister Gan Kim Yong revealed on September 27, 2023, that many firms are in discussions with the US administration regarding their eligibility for these exemptions.

The potential impact of the new tariffs on these companies may be limited, as they already intend to establish manufacturing capabilities in the US. On September 26, President Donald Trump announced a 100 percent tariff on branded or patented pharmaceutical products unless companies are building their manufacturing plants in America. This tariff is part of a broader set of measures affecting various sectors, set to take effect from October 1, 2023.

Impact on Singapore’s Pharmaceutical Sector

According to Gan, Singapore’s pharmaceutical exports to the US, valued at approximately S$4 billion (USD $3.1 billion), represent 13 percent of the nation’s total exports to the US. He noted that while the new tariffs primarily target patented and branded products, many non-branded items will not be affected.

Companies are working to confirm whether their planned manufacturing facilities in the US will qualify for tariff exemptions. Gan emphasized that discussions about tariff negotiations would occur at both government and corporate levels. “We will need to have some arrangement between Singapore and the US regarding the tariffs,” he stated. However, individual companies will also need to assess their specific investment plans in the US to determine their eligibility.

The Singapore government is proactively reaching out to major pharmaceutical firms to assess the potential impact of these tariffs. Gan anticipates that many of these companies, which often have diverse regional markets, will receive assistance in maintaining their competitiveness.

Long-term Investment Concerns

Gan expressed concerns about the long-term implications of these tariffs on investment patterns. He noted that countries that have established agreements with the US might redirect investments away from Singapore and the region. “This shift could impact the overall investment climate,” he warned, highlighting the need for Singapore to enhance its attractiveness for foreign investments.

As a response to the changing environment, the government plans to introduce a business adaptation grant in October 2023. This initiative aims to help affected companies adjust their supply chains and reconfigure production bases to mitigate the impact of the tariffs. Gan highlighted the government’s commitment to support businesses during this transition.

In addition to financial incentives, the Graduate Industry Traineeships programme will offer opportunities for fresh graduates, addressing potential job market concerns resulting from the economic uncertainty. Gan reiterated that while the pharmaceutical sector is crucial, companies must also explore new markets beyond the US.

Ultimately, Singapore’s goal is to negotiate a framework that ensures its pharmaceutical firms can continue to thrive in the US market while maintaining competitiveness globally. Gan emphasized the importance of realistic approaches to business viability in light of the tariffs, suggesting that long-term subsidies may not be feasible. The government is prepared to assist companies in restructuring their operations to adapt to the new trade landscape.